Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Figure 1

Overall mean change in visual acuity (VA) over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.